cardiovascular diseases

News

AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.

News

Cytokinetics' Myqorzo has succeeded where BMS's first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.

News

United Therapeutics will file ralinepag as a treatment for pulmonary arterial hypertension later this year, but can it compete in a crowded market?

News

Atrium Therapeutics has launched with $270m in funding and two preclinical siRNA candidates for rare genetic cardiomyopathies.

News

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.

News

A wireless sensor the size of a paperclip, Abbott's CardioMEMS HF, can now be used routinely by the NHS to monitor patients with heart failure.